您当前所在的位置:首页 > 产品中心 > 产品信息
Metaxalone_分子结构_CAS_1665-48-1)
点击图片或这里关闭

Metaxalone

产品号 DB00660 公司名称 DrugBank
CAS号 1665-48-1 公司网站 http://www.ualberta.ca/
分子式 C12H15NO3 电 话 (780) 492-3111
分子量 221.2524 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 542

产品价格信息

请登录

产品别名

标题
Metaxalone
IUPAC标准名
5-(3,5-dimethylphenoxymethyl)-1,3-oxazolidin-2-one
IUPAC传统名
@metaxalone
商标名
Skelaxin
Zorane
别名
Metazalone
Metaxalonum [Latin]
Metazolone
Metassalone [Dcit]
Metaxalon
Metaxalona [INN-Spanish]
Metaxalonum [INN-Latin]
Methaxalonum
Methoxolone

产品登记号

PubChem SID 46506253
PubChem CID 15459
CAS号 1665-48-1

产品性质

疏水性(logP) 2.3

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Metaxalone (marketed by King Pharmaceuticals under the brand name Skelaxin?) is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions. Its exact mechanism of action is not known, but it may be due to general central nervous system depression. It is considered to be a moderately strong muscle relaxant, with relatively low incidence of side effects. Skelaxin comes in an 800 mg scored tablet. It previously came in both 400 mg and 800 mg tablets. The 400 mg tablet has been discontinued. Possible side effects include nausea, vomiting, drowsiness and CNS side effects such as dizziness, headache, and irritability.
Indication For the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.
Pharmacology Metaxalone is a skeletal muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.
Toxicity LD50=775mg/kg (Rat, oral); LD50=1690 mg/kg (Mouse, oral). When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratoryfailure were noted as the dosage increased. In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes.
Affected Organisms
Humans and other mammals
Biotransformation Probably hepatic.
Absorption The absolute bioavailability of metaxalone from Skelaxin tablets is not known.
Half Life 9.2 (+/- 4.8) hours
Elimination Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.
Distribution * 800 L
Clearance * 68 +/- 50 L/h [Subjects received 1×400mg tablet under fasted conditions]
* 66 +/- 51 L/h [Subjects received 2×400 mg tablets under fasted conditions]
References
See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. [Pubmed]
Elenbaas JK: Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980 Oct;37(10):1313-23. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

参考文献

  • See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. Pubmed
  • Elenbaas JK: Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980 Oct;37(10):1313-23. Pubmed